Dramatic Improvement’ in Eyesight Problems with Aimspro
The results of the optic neuritis trial in Oxford are very good. Patients’ vision improved significantly following treatment with Aimspro.
The Multiple Sclerosis patients who took part in the double blind trial at the John Radcliffe Hospital showed improvement in visual field scores over a two week course of treatment.
These highly significant improvements in the patients’ sight were observed after only three injections, so the possibility of a placebo effect was excluded. There were no side effects.
This is the first time that any treatment has been shown conclusively to reduce an aspect of disability in the chronic phases of MS to this degree.
Dr BryanYoul, a consultant in Clinical Neurophysiology at the Royal Free Hospital in London, whose own findings on Aimspro in MS and other neurological conditions are about to be published, said: “These trial results are hugely significant and have wider implications for the treatment of MS."